Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4SCAR-276
- Development stage
- Phase 2
- Lead developer
- Shenzhen Geno-Immune Medical Institute
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous, Intrathecal, Intracerebroventricular, Intratumoral
01
Overview
4SCAR-276 is an autologous, fourth-generation chimeric antigen receptor (CAR) T cell therapy that targets CD276 (also known as B7-H3), a surface protein highly expressed on many tumor types but at low levels on normal tissues. The therapy uses patient-derived T cells genetically modified via lentiviral transduction to express a CAR specific for CD276, fused with an inducible apoptotic caspase 9 domain for safety. These engineered T cells are designed to recognize and kill tumor cells expressing CD276. The primary indication is refractory and/or recurrent solid tumors, including brain cancer and neuroblastoma. Developed by Shenzhen Geno-Immune Medical Institute, the drug is currently in clinical trials evaluating its safety and efficacy in patients with poor prognosis due to complex multimodal therapy resistance[1][5][8].
- Other names
- 4SCAR-CD276-modified T cells
02
Targets
B7-H3
Beyond the preview
Go deeper on 4SCAR-276.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4SCAR-276.